Headlines about Sangamo Therapeutics (NASDAQ:SGMO) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.6125523742589 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s rankings:
Shares of Sangamo Therapeutics traded up $0.15, reaching $15.30, on Tuesday, Marketbeat reports. The stock had a trading volume of 821,647 shares, compared to its average volume of 2,328,426. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 0.14. Sangamo Therapeutics has a fifty-two week low of $8.00 and a fifty-two week high of $27.50. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -21.86 and a beta of 2.92.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The firm had revenue of $12.60 million during the quarter, compared to analyst estimates of $53.09 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. Sangamo Therapeutics’s quarterly revenue was up 270.6% compared to the same quarter last year. research analysts predict that Sangamo Therapeutics will post -0.65 earnings per share for the current year.
Several analysts have commented on SGMO shares. BidaskClub downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 17th. ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Tuesday, May 1st. Bank of America started coverage on shares of Sangamo Therapeutics in a research report on Wednesday, June 20th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Wedbush reissued a “hold” rating and issued a $8.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $22.00.
In related news, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction on Friday, April 6th. The shares were sold at an average price of $17.41, for a total transaction of $87,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Curt A. Herberts III sold 8,163 shares of the company’s stock in a transaction on Friday, April 13th. The shares were sold at an average price of $20.00, for a total transaction of $163,260.00. Following the transaction, the vice president now owns 22,788 shares of the company’s stock, valued at $455,760. The disclosure for this sale can be found here. Insiders sold 38,163 shares of company stock valued at $669,860 over the last 90 days. 1.20% of the stock is owned by corporate insiders.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.